Evidence map›Paper›PMID 28862971›Full record

Observational studyJournal of the American Heart Association2017

Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease.

Ralph A H Stewart, Emil Hagström, Claes Held, Tom Kai Ming Wang, Paul W Armstrong, Philip E Aylward, Christopher P Cannon, Wolfgang Koenig, José Luis López-Sendón, Emile R Mohler and 8 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00799903 (LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00799903 phase3completednot on this map

LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

TypeinterventionalSponsorGlaxoSmithKlineRan2008 to 2013Enrolled15,828ConditionsAtherosclerosisArmsDarapladib, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ralph A H StewartAuckland City Hospital, Auckland, New Zealand rstewart@adhb.govt.nz.
Emil HagströmDepartment of Medical Sciences Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Claes HeldDepartment of Medical Sciences Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Tom Kai Ming WangAuckland City Hospital, Auckland, New Zealand.
Paul W ArmstrongCanadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
Philip E AylwardSouth Australian Health and Medical Research Institute, Flinders University and Medical Centre, Adelaide, Australia.
Christopher P CannonCardiovascular Division, Brigham and Women's Hospital, Boston, MA.
Wolfgang KoenigDeutsches Herzzentrum München, Technische Universität München, Munich, Germany.
José Luis López-SendónHospital Universitario La Paz IdiPaz, Madrid, Spain.
Emile R MohlerPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Nermin HadziosmanovicDepartment of Medical Sciences Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Susan Krug-GourleyMetabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, PA.
Marco Antonio Ramos CorralesSan Jose Satelite Hospital, Naucalpan de Juárez, Mexico.
Saulat SiddiquePunjab Medical Center Jail road Lahore, Punjab, Pakistan.
Philippe Gabriel StegDépartement Hospitalo-Universitaire FIRE, AP-HP Hôpital Bichat, Paris, France.
Harvey D WhiteAuckland City Hospital, Auckland, New Zealand.
Lars WallentinDepartment of Medical Sciences Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
STABILITY Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe major determinants and prognostic importance of self-reported health in patients with stable coronary heart disease are uncertain. METHODS AND

resultsThe STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial randomized 15 828 patients with stable coronary heart disease to treatment with darapladib or placebo. At baseline, 98% of participants completed a questionnaire that included the question, "Overall, how do you feel your general health is now?" Possible responses were

conclusionsSelf-reported health is strongly associated with geographical region, mood, and physical activity. In a global coronary heart disease population, self-reported health was independently associated with major cardiovascular events and mortality beyond what is measurable by established risk indicators. CLINICAL

trial registrationURL: http://www.ClinicalTrials.gov. Unique identifier: NCT00799903.

Indexed as

Patient Reported Outcome MeasuresSelf ReportAffectAgedBenzaldehydesBiphenyl CompoundsChi-Square DistributionChronic DiseaseCoronary DiseaseDiethylaminesExerciseFemaleHealth StatusHeart FailureHumansKaplan-Meier EstimateBenzaldehydesBiphenyl CompoundsdarapladibDiethylaminesOximesPhospholipase A2 InhibitorsPyrimidinonesSulfidescoronary artery diseasegeneral healthprognostic studies

Identifiers

PMID28862971
PMCPMC5586450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.